Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Palmer and colleagues present a computational model of drug additivity that can predict clinical efficacy for the majority of combination therapy trials in advanced cancer that led to US Food and Drug Administration approvals between 1995–2020.